Zappa, Francesco; Droege, Cornelia; Betticher, Daniel; von Moos, Roger; Bubendorf, Lukas; Ochsenbein, Adrian; Gautschi, Oliver; Oppliger Leibundgut, Elisabeth; Froesch, Patrizia; Stahel, Rolf; Hess, Thomas; Rauch, Daniel; Schmid, Petra; Mayer, Michael; Crowe, Susanne; Brauchli, Peter; Ribi, Karin; Pless, Miklos; on behalf of the Swiss Group for Clinical Cancer Research (SAKK), (2012). Bevacizumab and erlotinib (BE) first-line therapy in advanced non-squamous non-small-cell lung cancer (NSCLC) (stage IIIB/IV) followed by platinum-based chemotherapy (CT) at disease progression: A multicenter phase II trial (SAKK 19/05). Lung cancer, 78(3), pp. 239-44. Amsterdam: Elsevier 10.1016/S1359-6349(09)71860-9
Full text not available from this repository. (Request a copy)This phase II trial aimed to evaluate feasibility and efficacy of a first-line combination of targeted therapies for advanced non-squamous NSCLC: bevacizumab (B) and erlotinib (E), followed by platinum-based CT at disease progression (PD).
Item Type: |
Journal Article (Original Article) |
|---|---|
Division/Institute: |
04 Faculty of Medicine > Department of Haematology, Oncology, Infectious Diseases, Laboratory Medicine and Hospital Pharmacy (DOLS) > Clinic of Medical Oncology 04 Faculty of Medicine > Department of Haematology, Oncology, Infectious Diseases, Laboratory Medicine and Hospital Pharmacy (DOLS) > Clinic of Haematology and Central Haematological Laboratory |
UniBE Contributor: |
Ochsenbein, Adrian, Oppliger Leibundgut, Elisabeth |
ISSN: |
0169-5002 |
Publisher: |
Elsevier |
Language: |
English |
Submitter: |
Factscience Import |
Date Deposited: |
04 Oct 2013 14:28 |
Last Modified: |
05 Dec 2022 14:08 |
Publisher DOI: |
10.1016/S1359-6349(09)71860-9 |
PubMed ID: |
23009726 |
Web of Science ID: |
000311881400012 |
URI: |
https://boris.unibe.ch/id/eprint/10388 (FactScience: 216267) |
Actions (login required)
 |
Edit item |